Home > Journals > Minerva Endocrinologica > Past Issues > Articles online first > Minerva Endocrinologica 2020 Oct 26

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Endocrinologica 2020 Oct 26

DOI: 10.23736/S0391-1977.20.03271-X

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Increased serum IL-18 levels and IL-18R expression in newly diagnosed type 2 diabetes mellitus

Abhilasha BANKUL 1, Prasenjit MITRA 1, Smriti SURI 1, Indu SAXENA 2, Ravindra SHUKLA 3, Kamlakant SHUKLA 1, Praveen SHARMA 1

1 Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, India; 2 Department of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, India; 3 Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, Jodhpur, India


PDF


BACKGROUND: Type 2 Diabetes mellitus (T2DM) is a heterogeneous metabolic disorder in which genetic, sedentary lifestyle, obesity, and environmental factors come together to produce insulin resistance in target tissues, leading to hyperglycaemia. Evidence reveals that inflammation may play an essential role in the pathogenesis of T2DM. Interleukin-18 (IL-18), a proinflammatory cytokine, plays a crucial role in the acute and chronic inflammatory process. The association of IL-18 levels with IL-18R expression in T2DM has not been investigated so far. Aim of the study: to compare the peripheral changes in serum IL-18 levels and its receptor (IL18R) expression in newly diagnosed T2DM and healthy controls.
METHODS: A total of 35 newly diagnosed type 2 diabetic cases and 35 non-diabetic controls were enrolled after obtaining informed consent. Venous whole blood was taken under aseptic conditions. Biochemical parameters were estimated in an auto-analyzer. Serum IL-18 levels were calculated using ELISA, whereas IL-18R expression was determined via RT-PCR. GAPDH was used as an internal control.
RESULTS: When compared to non-diabetic controls, the serum IL-18 levels were significantly higher in T2DM patients (p=0.010) along with a significant upregulation of IL18R (p=0.0018). Serum IL-18 levels in T2DM and non-diabetic controls were 669.5 (445)and 498.3 (404.9) pg/ml respectively, and IL-18R showed a fold change of 10.33.
CONCLUSIONS: Both serum IL-18 and its receptor IL-18R is significantly higher in newly diagnosed T2DM patients.


KEY WORDS: Diabetes; Interleukin; Inflammation; Glycaemic status

top of page